Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics

Modern Rheumatology

Volumn 22, Issue 6, 2012, Pages 844-848

  Kubota, Ayako ^a   Nakamura, Takashi ^a   Miyazaki, Yoshiyasu ^a   Sekiguchi, Masayuki ^a   Suguro, Toru ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Biologics; Elective surgery; Perioperative complications; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TOCILIZUMAB;

ADOLESCENT; ADULT; AGED; ANKLE ARTHROPLASTY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTIVE SURGERY; FOOT SURGERY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SURGICAL INFECTION; TOTAL KNEE REPLACEMENT; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, ELECTIVE; SURGICAL WOUND INFECTION; WOUND HEALING;

EID: 84870359729     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0612-2     Document Type: Article

References (22)

1. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, et al. The role of TNF-A in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology. 2002;41:329-37.
2. Musacchio E, Valvason C, Botsios C, Ostuni F, Furlan A, Ramonda R, et al. The tumor necrosis factor-A blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells. J Rheumatol. 2009;36:1575-9.
3. Kudo O. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1-7.
4. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008;18:447-54.
5. Takeuchi T, Miyasaka N, InoueK,Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19:478-87.
6. Scanzello CR, Figgie MP, Nestor BJ, Goodman SM. Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J. 2006;2:141-7.
7. Fu X, Tian H, Hsu S, Wang D, Sheng Z. In vivo effects of tumor necrosis factor-A on incised wound and gunshot wound healing. J Trauma. 1996;40:140-3.
8. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55:333-7.
9. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-Alpha inhibition therapy. Foot Ankle Int. 2004;25: 331-5.
10. Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-Tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;3:689-95.
11. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25:430-6.
12. Guidelines of TNF inhibition therapy for rheumatoid arthritis (RA) (revised edition). Japan College of Rheumatology.
13. Adalimumab treatment guidelines for rheumatoid arthritis (RA). Japan College of Rheumatology.
14. Tocilizumab treatment guidelines for rheumatoid arthritis (RA) (2010 revised edition). Japan College of Rheumatology.
15. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20:250-78.
16. Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N. Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J. 2002;16: 963-74.
17. Alves-Rosa MF, Palermo MS, Isturiz MA. Enhancement of immune complex clearance by TNF-Alpha in a murine model. Clin Immunol Immunopathol. 1998;89:214-21.
18. Gallucci RM, Simeonova PP, Matheson JM, Kommineni C, Guriel JL, Sugawara T, Luster MI. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 2000;14:2525-31.
19. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factoralpha blockers: perioperative interruption of tumour necrosis factor-Alpha blockers decreases complications? Rheumatology (Oxford). 2010;49:341-7.
20. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005;44:157-63.
21. Nederlandse Vereniging voor Reumatologie. Medicijnen: het toepassen van TNF blockade in de behandeling vav reumatoide arthritis. Utrecht: Dutch Society for Rheumatology; 2003.
22. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59:762-84.